Nutrition-Gut-Brain Interactions Research Centre, Faculty of Health and Medicine, School of Medical Sciences, Örebro University, Örebro, Sweden.
Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
Clin Transl Gastroenterol. 2019 Apr;10(4):e00034. doi: 10.14309/ctg.0000000000000034.
OBJECTIVES: Fecal microbiota transfer (FMT) is suggested as a potential treatment for patients with irritable bowel syndrome (IBS). We aimed to study the effect of allogenic and autologous FMT on IBS symptoms, visceral sensitivity, and compositional changes in fecal and mucosa-adherent microbiota. METHODS: Seventeen patients with IBS were randomized either to receive fecal material from a healthy donor (allogenic) or to receive their own fecal material (autologous). The fecal material was administered into the cecum by whole colonoscopy after bowel cleansing. RESULTS: No significant differences were found between the allogenic and the autologous FMT regarding symptom scores. However, symptom scores of patients receiving allogenic fecal material significantly decreased after FMT compared with baseline (P = 0.02), which was not the case in the autologous group (P = 0.16). Visceral sensitivity was not affected except for a small beneficial effect on urge scores in the autologous group (P < 0.05). While both fecal and mucosa-adherent microbiota of some patients shifted to their respective donor's fecal microbiota, some patients showed no relevant microbial changes after allogenic FMT. Large compositional shifts in fecal and mucosa-adherent microbiota also occurred in the autologous group. CONCLUSIONS: This study showed that a single FMT by colonoscopy may have beneficial effects in IBS; however, the allogenic fecal material was not superior to the autologous fecal material. This suggests that bowel cleansing prior to the colonoscopy and/or processing of the fecal material as part of the FMT routine contribute to symptoms and gut microbiota composition changes in IBS.
目的:粪便微生物群移植(FMT)被认为是治疗肠易激综合征(IBS)患者的一种潜在方法。我们旨在研究异体和自体 FMT 对 IBS 症状、内脏敏感性以及粪便和黏膜黏附微生物群落组成变化的影响。
方法:17 名 IBS 患者被随机分为接受健康供体粪便物质(异体)或接受自己粪便物质(自体)组。粪便物质在肠道清洁后通过全结肠镜进入盲肠。
结果:异体和自体 FMT 在症状评分方面没有显著差异。然而,接受异体粪便物质的患者在 FMT 后症状评分明显低于基线(P = 0.02),而自体组则不然(P = 0.16)。除了自体组的冲动评分有较小的有益影响外,内脏敏感性没有受到影响。虽然一些患者的粪便和黏膜黏附微生物群落都转移到了各自供体的粪便微生物群落,但有些患者在接受异体 FMT 后没有相关的微生物变化。在自体组中,粪便和黏膜黏附微生物群落也发生了较大的组成变化。
结论:本研究表明,结肠镜下单次 FMT 可能对 IBS 有益,但异体粪便物质并不优于自体粪便物质。这表明结肠镜检查前的肠道清洁和/或 FMT 常规中粪便处理有助于 IBS 症状和肠道微生物群落组成的变化。
NPJ Biofilms Microbiomes. 2024-8-28
Biologics. 2025-8-21
Gut Microbiome (Camb). 2022-8-25
NPJ Biofilms Microbiomes. 2024-8-28
Signal Transduct Target Ther. 2024-6-8
Aliment Pharmacol Ther. 2017-1